CARA Insider Trading

Insider Ownership Percentage: 3.10%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $0.00

Cara Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at Cara Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$200k-$100k$0$100k$200kTotal Insider BuyingTotal Insider Selling

Cara Therapeutics Share Price & Price History

Current Price: $0.00
Price Change: +0.30 (1.20%)
As of 04/15/2025 06:33 PM ET

This chart shows the closing price history over time for CARA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMarApr$15.96Closing price on 04/15/25:

SEC Filings (Institutional Ownership Changes) for Cara Therapeutics (NASDAQ:CARA)

44.66% of Cara Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CARA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1$0Total InflowsTotal Outflows
Cara Therapeutics logo
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Read More on Cara Therapeutics

Today's Range

Now: N/A

50 Day Range

MA: $15.19
Low: $13.29
High: $17.10

52 Week Range

Now: N/A

Volume

237,144 shs

Average Volume

23,945 shs

Market Capitalization

$24.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.41

Who are the company insiders with the largest holdings of Cara Therapeutics?

Cara Therapeutics' top insider investors include:
  1. Christopher Posner (CEO)
  2. Frederique PhD Menzaghi (SVP)
  3. Scott Terrillion (Insider)
  4. Joana Goncalves (Insider)
  5. Ryan D Maynard (CFO)
Learn More about top insider investors at Cara Therapeutics.

Who are the major institutional investors of Cara Therapeutics?

Cara Therapeutics' top institutional investors include:
  1. Simplex Trading LLC — 0.00%
Learn More about top institutional investors of Cara Therapeutics stock.

Which institutional investors are selling Cara Therapeutics stock?

During the last quarter, CARA stock was sold by these institutional investors:
  1. Simplex Trading LLC